Verve Therapeutics

Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan and Burt A. Adelman in 2018 and is headquartered in Boston, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.

Cathie Wood has been steadily buying Verve Therapeutics shares this summer. An upcoming data readout could be a game changer for the company and its shareholders.

1 Cathie Wood Stock That Could Go Parabolic Soon

Verve Therapeutics (VERV) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.84 per share a year ago.

Verve Therapeutics (VERV) Reports Q2 Loss, Tops Revenue Estimates

heart-1 Initial Clinical Data Expected in the Fourth Quarter of 2023 Preclinical Studies and Clinical Operations Activities Underway to Support Initiation of Clinical Trials for VERVE-102 and VERVE-201 in 2024 Lp(a) Program Advancing in Collaboration with Lilly; Received $60 Million in Combined Upfront Payment and Equity Investment in August 2023 Well-capitalized with Cash Runway into 2026 BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported recent company progress and financial results for the second quarter of 2023. “We are dedicated to bringing life-changing, once-and-done medicines to patients with cardiovascular disease,” said Sekar Kathiresan, M.D.

Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results

BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the Canaccord 43rd Annual Growth Conference on Thursday, August 10, 2023 at 11:30 a.m. ET in Boston.

Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 93.5% in Verve Therapeutics (VERV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Verve Therapeutics (VERV)? Wall Street Analysts Think 93.5%

Cathie Wood has been buying a lot of Verve Therapeutics stock recently. It's a gene-editing biotech that's just starting its first clinical trials.

Cathie Wood Is Buying This Biotech, but Here's Why I'm Not

Verve, which was founded in 2018 and went public in June 2021, is developing gene-editing treatments, delivered through a single, intravenous infusion, for atherosclerotic cardiovascular disease.

Verve Therapeutics Gains 20.74% In June as Ark Funds Invest

Verve's (VERV) shares rise on collaboration with Eli Lilly to develop gene editing treatment for cardiovascular disease.

Verve (VERV) Up 9.9% in a Week on Collaboration With Eli Lilly

Verve to Receive $60 Million in Combined Upfront Payment and Equity Investment; Additional Capital Positioned to Extend Verve's Expected Cash Runway into 2026

Verve Establishes Global Collaboration with Lilly to Advance Verve's In Vivo Gene Editing Program Targeting Lp(a) for the Treatment of Atherosclerotic Cardiovascular Disease

BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat during the 2023 Jefferies Healthcare Conference on Thursday, June 8, 2023 at 3:00 p.m. ET in New York.

Verve Therapeutics to Participate in the 2023 Jefferies Healthcare Conference

BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat during the Stifel 2023 Tailoring Genes: Virtual Genetic Medicines Day on Tuesday, May 30, 2023 at 4:10 p.m. ET.

Verve Therapeutics to Participate in the Stifel 2023 Tailoring Genes: Virtual Genetic Medicines Day

heart-1 Clinical Trial of VERVE-101 Ongoing with Initial Data Expected in the Second Half of 2023 VERVE-102 Named Second PCSK9-Targeting Program, Leveraging Novel GalNAc-LNP Delivery with Clinical Trial Initiation Expected in the First Half of 2024 VERVE-201 Targeting ANGPTL3 Progressing with Clinical Trial Initiation Expected in the Second Half of 2024 Well-capitalized with $508.7 Million Supporting Runway into the Second Half of 2025 BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported pipeline progress and financial results for the first quarter of 2023. “The focus at Verve is to develop life-changing medicines for people with cardiovascular disease,” said Sekar Kathiresan, M.D.

Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results

BioXcel Therapeutics

CRISPR Therapeutics

A fair number of Nasdaq-listed growth stocks moved higher this week. CRISPR Therapeutics, BioXcel Therapeutics, and Verve Therapeutics were among the biggest winners this week.

Why These 3 Nasdaq Stocks Were Glowing Green This Week

BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat during the RBC Capital Markets 2023 Global Healthcare Conference on Tuesday, May 16, 2023 at 9:30 a.m. ET in New York.

Verve Therapeutics to Participate in the RBC Capital Markets 2023 Global Healthcare Conference

Verve Therapeutics, Inc. is developing a CRISPR-based editing gene therapy for cardiovascular diseases. Verve's lead assets are VERVE-101 for HeFH and ASCVD and VERVE-201 for HoFH.

Verve: Spiffy Biotech That Cathie Wood Bought, Initiating With A Hold Rating

ARK Innovation ETF

Beam Therapeutics

Coinbase

Ginkgo Bioworks Holdings

Intellia Therapeutics

Cathie Wood-led ARK Investment Management raised stakes in a number of biotech companies on Wednesday with these stocks recording negative returns over the last one month, potentially making them attractive in terms of valuations.

Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global

BOSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat during the Guggenheim 2023 Genomic Medicines and Rare Disease Day on Monday, April 3, 2023 at 10:45 a.m. ET in NYC.

Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day

Editas Medicine

Novartis

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

These CRISPR stocks could be big winners for patient investors.

Investing in Top CRISPR Companies

Verve Therapeutics is a gene editing company focused on revolutionizing the treatment of cardiovascular diseases. The company's research focuses on two genes, PCSK9 and ANGPTL3 - the lead product candidate, VERVE-101, aims to treat Heterozygous Familial Hypercholesterolemia (HeFH).

Verve Therapeutics: VERVE-101 On Hold, But Technology Remains Sound

VERVE-201 Preclinical Data Supports Advancement of Drug Candidate Toward Clinical Development for Homozygous Familial Hypercholesterolemia, with Initiation of Clinical Trial Anticipated in 2024

Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates

heart-1 Clinical Trial of VERVE-101 Ongoing in New Zealand and UK; Data from Dose Escalation Cohorts Expected in the Second Half of 2023

Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

Verve Therapeutics has been stuck with a clinical hold. There is no good reason the hold will not be lifted, say within a year or less.

Verve Therapeutics: Opportunity For Quick Profit On Eventual Lifting Of Clinical Hold

PDS Biotechnology Corporation

These cutting-edge biotech stocks hold tremendous upside potential.

3 Deeply Undervalued Stocks That Could Double Your Money

BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that VERVE-101 has been awarded the Innovation Passport for the treatment of heterozygous familial hypercholesterolemia (HeFH) under the Innovative Licensing and Access Pathway (ILAP) by the Medicines and Healthcare products Regulatory Agency (MHRA), the regulatory body of the United Kingdom (UK). The ILAP aims to accelerate time to market and facilitate patient access to innovative medicines. VERVE-101 is a novel, investigational gene editing medicine designed to be a single-course treatment that permanently turns off the PCSK9 gene in the liver to durably lower disease-driving low-density lipoprotein cholesterol (LDL-C). Innovation Passport is the first step in the ILAP process and is awarded for a medicinal product addressing a condition that is life-threatening or seriously debilitating and where there is a significant patient or public health need.

Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial Hypercholesterolemia

Cellectis SA

Sangamo Therapeutics

CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis.

News for Verve Therapeutics Stock (VERV)